Differentiating Hodgkin Lymphoma and Sarcoid Reaction in Subsequent FDG-PET/CT: A Case Report and Literature Review.

IF 0.6 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

World Journal of Nuclear Medicine Pub Date : 2023-12-26 eCollection Date: 2023-12-01 DOI:10.1055/s-0043-1777694

Obayda Rabei, Ula Al-Rasheed, Mohammed Alrammahi, Akram Al-Ibraheem

{"title":"Differentiating Hodgkin Lymphoma and Sarcoid Reaction in Subsequent FDG-PET/CT: A Case Report and Literature Review.","authors":"Obayda Rabei, Ula Al-Rasheed, Mohammed Alrammahi, Akram Al-Ibraheem","doi":"10.1055/s-0043-1777694","DOIUrl":null,"url":null,"abstract":"<p><p>Sarcoidosis is frequently associated with various hematological and solid tumors; it can be discovered by chance during tumor evaluations. Sarcoidosis can occur before some cancers, coexist with others, or be diagnosed 1 to 2 years later. Sarcoid reaction affecting hilar and mediastinal lymph nodes can pose a diagnostic challenge in patients with histopathological confirmation of Hodgkin lymphoma who are being evaluated using fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) scan because it cannot be easily distinguished from lymphoma infiltration. The presence of an increase or persistence of a prominent activity on a follow-up FDG-PET/CT scan after chemotherapy treatment for lymphoma that is associated with a complete metabolic response in the site of the primarily diagnosed lymphomatous disease is highly suggestive of concurrent sarcoidosis and necessitates careful assessment to avoid unnecessary therapy.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751130/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1777694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Sarcoidosis is frequently associated with various hematological and solid tumors; it can be discovered by chance during tumor evaluations. Sarcoidosis can occur before some cancers, coexist with others, or be diagnosed 1 to 2 years later. Sarcoid reaction affecting hilar and mediastinal lymph nodes can pose a diagnostic challenge in patients with histopathological confirmation of Hodgkin lymphoma who are being evaluated using fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) scan because it cannot be easily distinguished from lymphoma infiltration. The presence of an increase or persistence of a prominent activity on a follow-up FDG-PET/CT scan after chemotherapy treatment for lymphoma that is associated with a complete metabolic response in the site of the primarily diagnosed lymphomatous disease is highly suggestive of concurrent sarcoidosis and necessitates careful assessment to avoid unnecessary therapy.

查看原文本刊更多论文

在随后的 FDG-PET/CT 中鉴别霍奇金淋巴瘤和肉芽肿反应：病例报告和文献综述。

肉样瘤病经常与各种血液肿瘤和实体瘤相关；它可能在肿瘤评估时偶然被发现。肉样瘤病可能发生在某些癌症之前，也可能与其他癌症并存，或在 1 到 2 年后才被诊断出来。对于组织病理学确诊为霍奇金淋巴瘤并正在接受氟脱氧葡萄糖-正电子发射计算机断层扫描（FDG-PET/CT）评估的患者来说，影响肺门淋巴结和纵隔淋巴结的肉样瘤反应会给诊断带来挑战，因为肉样瘤反应不易与淋巴瘤浸润区分开来。如果淋巴瘤化疗后的随访 FDG-PET/CT 扫描中出现明显的活动性增加或持续存在，且与主要确诊淋巴瘤疾病部位的完全代谢反应相关联，则高度提示并发肉样瘤病，有必要进行仔细评估，以避免不必要的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Nuclear Medicine RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

自引率

16.70%

发文量

118

审稿时长

48 weeks